I am so glad to see that the MHRA is on board with Leronlimab manufacturing processes and with Leronlimab safety. Therefore, this sets us up very nicely for a "fast track" approval on P2 m to m, based on the third and final component; namely, Leronlimab efficacy. Just another day or two!